Hereditary haemorrhagic telangiectasia: Pathophysiology, diagnosis and treatment

Blood Reviews

Volumn 24, Issue 6, 2010, Pages 203-219

  Shovlin, Claire L ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Arteriovenous malformation; Bevazicimub; Epistaxis; Guidelines; Hypoxaemia; Iron; Nose bleeds; Pulmonary; Randomised control trial; Screening; TGF beta; Thalidomide; Thrombosis

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; ANTIFIBRINOLYTIC AGENT; BEVACIZUMAB; ENDOGLIN; ESTROGEN; HEPARIN; PLACEBO; PROGESTERONE; PROTEIN ALK 1; PROTHROMBIN; RALOXIFENE; RECEPTOR PROTEIN; SMAD4 PROTEIN; TAMOXIFEN; THALIDOMIDE; TRANEXAMIC ACID; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WARFARIN;

AGE DISTRIBUTION; ARTERIAL THROMBOEMBOLISM; ARTERIOVENOUS MALFORMATION; ARTERY THROMBOSIS; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; BLEEDING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG CONTRAINDICATION; DRUG MEGADOSE; DRUG SAFETY; ECHOCARDIOGRAPHY; ENDOCARDITIS; EPISTAXIS; GENE FUNCTION; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; HEMODYNAMIC PARAMETERS; HETEROZYGOSITY; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HYPERTENSION; IRON DEFICIENCY ANEMIA; IRON THERAPY; LIVER FUNCTION TEST; LUNG FUNCTION TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RENDU OSLER WEBER DISEASE; SCREENING TEST; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

HUMANS; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 77955880114     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2010.07.001     Document Type: Article

References (229)

1. Guttmacher A.E., Marchuk D.A., White R.I. Hereditary hemorrhagic telangiectasia. New Engl J Med 1995, 333:918-924.
2. Shovlin C.L., Guttmacher A.E., Buscarini E., et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000, 91:66-67.
3. Govani F., Shovlin C. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009, 17:860-871.
4. Kjeldsen A.D., Vase P., Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med 1999, 245:31-39.
5. Dakeishi M., Shioya T., Wada Y., et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mut 2002, 19:140-148.
6. Bideau A., Brunet G., Heyer E., Plauchu H., Robert J.-M. An abnormal concentration of cases of Rendu-Osler disease in the Valserine valley of the French Jura: a geneological and demographic study. Ann Hum Biol 1992, 19:233-247.
7. Westermann C.J., Rosina A.F., Vries V.D., de Coteau P.A. The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: a family screening. Am J Med Genet 2003, 116:324-328.
8. Lesca G., Genin E., Blachier C., et al. Hereditary hemorrhagic telangiectasia: evidence for regional founder effects of ACVRL1 mutations in French and Italian patients. Eur J Hum Genet 2008, 16:742-749.
9. Lacout A., Pelage J., Lesur G., et al. Pancreatic involvement in hereditary hemorrhagic telangiectasia: assessment with multidetector helical CT. Radiology 2010, 254:479-484.
10. Trembath R., Thomson J., Machado R., et al. Clinical and molecular features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. New Engl J 2001, 345:325-334.
11. Gallione C., Repetto G.M., Legius E., et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia is associated with mutations in MADH4 (SMAD4). Lancet 2004, 363:852-859.
12. Brohée D., Franken P., Fievez M., et al. High-output right ventricular failure secondary to hepatic arteriovenous microfistulae Selective arterial embolization treatment. Arch Intern Med 1984, 144:1282-1284.
13. Haitjema T., ten Berg J., Overtoom T.T., Ernst J.M., Westermann C.J.J. Unusual complications after embolization of a pulmonary arteriovenous malformation. Chest 1996, 109:1401-1404.
14. Boillot O., Bianco F., Viale J.-P., et al. Liver transplantation resolves the hyperdynamic circulation in hereditary hemorrhagic telangiectasia with hepatic involvement. Gastroenterology 1999, 116:187-192.
15. Garcia-Tsao G., Korzenik J.R., Young L., et al. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2000, 343:931-936.
16. Shovlin C.L., Tighe H.C., Davies R.J., Gibbs J.S.R., Jackson J.E. Embolisation of pulmonary arteriovenous malformations: no consistent effect on pulmonary artery pressure. Eur Resp J 2008, 32:162-169.
17. Shovlin C.L., Sulainam N.L., Govani F.S., Jackson J.E., Begbie M.E. Elevated Factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost 2007, 98:1031-1039.
18. Cirulli A., Loria M.P., Dambra P., et al. Patients with Hereditary Hemorrhagic Telangectasia (HHT) exhibit a deficit of polymorphonuclear cell and monocyte oxidative burst and phagocytosis: a possible correlation with altered adaptive immune responsiveness in HHT. Curr Pharm Des 2006, 12:1209-1215.
19. McAllister K.A., Grogg K.M., Johnson D.W., et al. Endoglin, a TGF-ß binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994, 8:345-351.
20. Johnson D.W., Berg J.N., Baldwin M.A., et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996, 13:189-195.
21. accessed April 2008. http://www.hhtmutation.org.
22. Kjeldsen A.D., Møller T.R., Brusgaard K., et al. Clinical symptoms according to genotype amongst patients with hereditary haemorrhagic telangiectasia. J Int Med 2005, 258:349-355.
23. Letteboer T.G.W., Mager J.J., Snijder R.J., et al. Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. J Med Genet 2006, 43:371-377.
24. Bossler A.D., Richards J., George C., Godmilow L., Ganguly A. Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype. Hum Mutat 2006, 27:667-675.
25. Bayrak-Toydemir P., McDonald J., Markewitz B., et al. Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia. Am J Med Genet A 2006, 140:463-470.
26. Sabbà C., Pasculli G., Lenato G.M., et al. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost 2007, 5:1149-1157.
27. Lesca G., Olivieri C., Burnichon N., et al. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. Genet Med 2007, 9:14-22.
28. Park S., Wankhede M., Lee Y., et al. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest 2009, 119:3487-3496.
29. Belik J., Jerkic M., McIntyre B., et al. Age-dependent endothelial nitric oxide synthase uncoupling in pulmonary arteries of endoglin heterozygous mice. Am J Physiol Lung Cell Mol Physiol 2009, 297:L1170-L1178.
30. Mahmoud M., Allinson K., Zhai Z., et al. Pathogenesis of arteriovenous malformations in the absence of endoglin. Circ Res 2010, 106:1425-1433.
31. Lebrin F., Srun S., Raymond K., et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010, 16:420-428.
32. Faughnan M., Palda V., Garcia-Tsao G., et al. International guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. J Med Genet 2009, [Jun 29. [Epub ahead of print]]. doi:10.1136/jmg.2009.069013.
33. Hoag J., Terry P., Mitchell S., Reh D., Merlo C. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 2010, 120:838-843.
34. Shovlin C.L., Jackson J.E., Bamford K., et al. Primary determinants of ischaemic stroke/ brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Thorax 2008, 63:259-266.
35. Harvey R.J., Kanagalingam J., Lund V.J. The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Am J Rhinol 2008, 22:182-187.
36. Richmon J., Tian Y., Husseman J., Davidson T. Use of a sprayed fibrin hemostatic sealant after laser therapy for hereditary hemorrhagic telangiectasia epistaxis. Am J Rhinol 2007, 21:187-191.
37. Pagella F., Colombo A., Matti E., et al. Correlation of severity of epistaxis with nasal telangiectasias in hereditary hemorrhagic telangiectasia (HHT) patients. Am J Rhinol Allergy 2009, 23:52-58.
38. Braak S.J., de Witt C.A., Disch F.J., Overtoom T.T., Westermann J.J. Percutaneous embolization on hereditary hemorrhagic telangiectasia patients with severe epistaxis. Rhinology 2009, 47:166-171.
39. Lesnik G.T., Ross D.A., Henderson K.J., Joe J.K., Leder S.B., White R.I. Septectomy and septal dermoplasty for the treatment of severe transfusion-dependent epistaxis in patients with hereditary hemorrhagic telangiectasia and septal perforation. Am J Rhinol 2007, 21:312-315.
40. de Gussem E., Snijder R., Disch F., Zanen P., Westermann C., Mager J. The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study. Rhinology 2009, 47:85-88.
41. Fernandez L.A., Garrido-Martin E.M., Sanz-Rodriguez F., et al. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. Thromb Haemost 2007, 97:254-262.
42. Morales-Angulo C., Perez del Molino A., Zarrabeitia R., Fernandez A., Sanz-Rodriguez F., Botella L.M. Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid. Acta Otorrinolaringol Esp 2007, 58:129-132.
43. Simonds J., Miller F., Mandel J., Davidson T. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009, 119:988-992.
44. Davidson T., Olitsky S., Wei J. Hereditary hemorrhagic telangiectasia/avastin. Laryngoscope 2010, 120:432-435.
45. Albinana V., Bernabeu-Herrero M.E., Zarrabeitia R., Bernabeu C., Botella L.M. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): effects of raloxifene, on endoglin and ALK1 expression in endothelial cells. Thromb Haemost 2010, 103:525-534.
46. Yaniv E., Preis M., Hadar T., Shvero J., Haddad M. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope 2009, 119:284-288.
47. Gazzaniga P., Buscarini E., Leandro G., et al. Contrast echocardiography for pulmonary arteriovenous malformations (PAVMs) screening: does any bubble matter?. Eur J Echocardiogr 2008, 10:513-518.
48. Parra J., Bueno J., Zarauza J., et al. Graded contrast echocardiography in pulmonary arteriovenous malformations. Eur Respir J 2010, 35:1279-1285.
49. Zukotynski K., Chan R., Chow C., Cohen J., Faughnan M. Contrast echocardiography grading predicts pulmonary arteriovenous malformations on CT. Chest 2007, 132:18-23.
50. van Gent M.W., Post M.C., Luermans J.G., et al. Screening for pulmonary arteriovenous malformations using transthoracic contrast echocardiography: a prospective study. Eur Respir J 2009, 33:85-91.
51. van Gent M.W., Post M.C., Snijder R.J., et al. Grading of pulmonary right-to-left shunt with transthoracic contrast echocardiography: does it predict the indication for embolotherapy?. Chest 2008, 135:1288-1292.
52. van Gent M.W., Post M.C., Snijder R.J., Westermann C.J., Plokker H.W., Mager J.J. Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography study. Chest 2010, [Feb 12. [Epub ahead of print]] doi:10.1378/chest.09-1849.
53. Thenganatt J., Schneiderman J., Hyland R., Edmeads J., Mandzia J., Faughnan M. Migraines linked to intrapulmonary right-to-left shunt. Headache 2006, 46:439-443.
54. Marziniak M., Jung A., Guralnik V., Evers S., Prudlo J., Geisthoff U. An association of migraine with hereditary haemorrhagic telangiectasia independently of pulmonary right-to-left shunts. Cephalalgia 2009, 29:76-81.
55. Shovlin C.L., Sodhi V., McCarthy A., Lasjaunias P., Jackson J.E., Sheppard M.N. Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia: suggested approach for obstetric services. BJOG 2008, 115:1108-1115.
56. Post M., Thijs V., Schonewille W., et al. Embolization of pulmonary arteriovenous malformations and decrease in prevalence of migraine. Neurology 2006, 66:202-205.
57. Remy-Jardin M., Dumont P., Brillet P., Dupuis P., Duhamel A., Remy J. Pulmonary arteriovenous malformations treated with embolotherapy: helical CT evaluation of long-term effectiveness after 2-21-year follow-up. Radiology 2006, 239:576-585.
58. Pollak J.S., Saluja S., Thabet A., Henderson K.J., White R.I. Clinical and anatomic outcomes after embolotherapy of pulmonary arteriovenous malformations. J Vasc Interv Radiol 2006, 17:35-45.
59. Hart JL, Aldin Z, Braude P, Shovlin CL, Jackson J. Embolization of pulmonary arteriovenous malformations using the Amplatzer vascular plug: successful treatment of 69 consecutive patients Eur J Radiology. 2010 [June 24, Electronic publication ahead of print]. http://doi:10.1007/s00330-010-1851-2.
60. Letourneau-Guillon L., Faughnan M.E., Soulez G., et al. Embolization of pulmonary arteriovenous malformations with amplatzer vascular plugs: safety and midterm effectiveness. J Vasc Interv Radiol 2010, 21:649-656.
61. Brillet P.Y., Dumont P., Bouaziz N., et al. Pulmonary arteriovenous malformation treated with embolotherapy: systemic collateral supply at multidetector CT angiography after 2-20-year follow-up. Radiology 2007, 242:267-276.
62. Shovlin C.L., Gibbs J.S.R., Jackson J.E. Management of pulmonary arteriovenous malformations in pulmonary hypertensive patients. A pressure to embolise?. Eur Respir Rev 2008, 18:4-6.
63. Wilson W., Taubert K., Gewitz M., et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. J Am Dent Assoc 2008, 138(739-745):747-760.
64. Wray D., Ruiz F., Richey R., Stokes T. Guideline Development Group. Prophylaxis against infective endocarditis for dental procedures-summary of the NICE guideline. Br Dent J 2008, 204:555-557.
65. Shovlin C.L., Bamford K.B., Wray D. Post-NICE 2008: Antibiotic prophylaxis prior to dental procedures for patients with pulmonary arteriovenous malformations (PAVMs) and hereditary haemorrhagic telangiectasia. Br Dent J 2008, 205:531-533.
66. Shovlin CL, Jackson JE. Pulmonary arteriovenous malformations. In: Pulmonary Circulation 3rd Edition, Arnold. Eds Peacock A, Rubin LJ; in press.
67. Krings T., Ozanne A., Chng S., Alvarez H., Rodesch G., Lasjaunias P. Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1day-60years. Neuroradiology 2005, 47:711-720.
68. Krings T., Chng S.M., Ozanne A., Alvarez H., Rodesch G., Lasjaunias P.L. Hereditary hemorrhagic telangiectasia in children: endovascular treatment of neurovascular malformations. Results in 31 patients. Neuroradiology 2005, 47:946-954.
69. Dauwerse L., Abma T.A., Wolbers J.G. A patient's journey: the war in my head: coping with arteriovenous malformation after a brain haemorrhage. BMJ 2010, 340:b5400.
70. Gincul R., Lesca G., Gelas-Dore B., et al. Evaluation of previously nonscreened hereditary hemorrhagic telangiectasia patients shows frequent liver involvement and early cardiac consequences. Hepatology 2008, 48:1377-1379.
71. Wanless I.R., Gryfe A. Nodular transformation of the liver in hereditary hemorrhagic telangiectasia. Arch Pathol Lab Med 1986, 110:331-335.
72. Van Gent MWF, Post MC, Mager JJ, et al. Diagnostic Curacao Criteria for HHT; are they still valid? Hematology Meeting Rep 2009; 3 (4) 13.
73. Buscarini E., Plauchu H., Garcia Tsao G., et al. Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations. Liver Int 2006, 26:1040-1046.
74. Dupuis-Girod S., Chesnais A., Ginon I., et al. Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study. Liver Transplant 2010, 16:340-347.
75. Lerut J., Orlando G., Adam R., et al. Liver transplantation for hereditary hemorrhagic telangiectasia: report of the European liver transplant registry. Ann Surg 2006, 244:854-862.
76. Cura M., Postoak D., Speeg K., Vasan R. Transjugular intrahepatic portosystemic shunt for variceal hemorrhage due to recurrent of hereditary hemorrhagic telangiectasia in a liver transplant. J Vasc Interv Radiol 2010, 21:135-139.
77. Mitchell A., Adams L.A., MacQuillan G., Tibballs J., vanden Driesen R., Delriviere L. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 2008, 14:210-213.
78. Buscarini E., Manfredi G., Zambelli A. Bevacizumab to treat complicated liver vascular malformations in hereditary hemorrhagic telangiectasia: a word of caution. Liver Transpl 2008, 14:1685-1686.
79. Poisson A., Vasdev A., Brunelle F., Plauchu H., Dupuis-Girod S. Acute paraplegia due to spinal arteriovenous fistula in two patients with hereditary hemorrhagic telangiectasia. Eur J Pediatr 2009, 168:135-139.
80. Cullen C., Alvarez H., Rodesch G., Lasjaunias P. Spinal arteriovenous shunts presenting before 2years of age: analysis of 13 cases. Childs Nerv Syst 2006, 22:1103-1110.
81. Espinosa P.S., Pettigrew L.C., Berger J.R. Hereditary hemorrhagic telangectasia and spinal cord infarct: case report with a review of the neurological complications of HHT. Clin Neurol Neurosurg 2008, 110:484-491.
82. Sense about Science. Making Sense of Screening. 2009. http://wwwsenseaboutscienceorguk/PDF/MSOScreeningpdf.
83. Raffle A., Gray M. Screening 2007, Oxford University Press, Evidence and practice, http://www.oup.com.
84. Chodick G., Ronckers C., Shalev V., Ron E. Excess lifetime cancer mortality risk attributable to radiation exposure from computed tomography examinations in children. Isr Med Assoc J 2007, 9:584-587.
85. Rice H., Frush D., Farmer D., Waldhausen J. APSA Education Committee Review of radiation risks from computed tomography: essentials for the pediatric surgeon. J Pediatr Surg 2007, 42:603-607.
86. Thierry-Chef I., Simon S.L., Land C.E., Miller D.L. Radiation dose to the brain and subsequent risk of developing brain tumors in pediatric patients undergoing interventional neuroradiology procedures. Radiat Res 2008, 170:553-565.
87. Román G., Fisher M., Perl D.P., Poser C.M. Neurological manifestations of hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber Disease): report of 2 cases and review of the literature. Ann Neurol 1978, 4:130-144.
88. Maher C.O., Piepgras D.G., Brown R.D., Friedman J.A., Pollak B.E. Cerebrovascular manifestations in 321 cases of hereditary haemorrhagic telangiectasia. Stroke 2001, 32:877-882.
89. Braverman I.M. Ultrastructure and organization of the cutaneous microvasculature in normal and pathologic states. J Invest Dermatol 1989, 93:2S-9S.
90. Braverman I.M., Keh A., Jacobson B.S. Ultrastructure and three-dimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia. J Invest Dermatol 1990, 95:422-427.
91. Cooley D., McNamara D. Pulmonary telangiectasia: report of a case proven by pulmonary biopsy. J Thorac Surg 1954, 27:614.
92. Hales M. Multiple small arteriovenous fistulas of the lungs. Am J Path 1956, 32:927-937.
93. Shovlin C.L., Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999, 54:714-729.
94. Wolinsky H., Glagov S. A lamellar unit of aortic medial structure and function in mammals. Circ Res 1967, 20:99-111.
95. Owens C.D. Adaptive changes in autogenous vein grafts for arterial reconstruction: clinical implications. J Vasc Surg 2010, 51:736-746.
96. Yater W., Finnegan J., Giffin H. Pulmonary arteriovenous fistula (varix). JAMA 1949, 141:581-589.
97. Bourdeau A., Cymerman U., Paquet M.-E., et al. Endoglin expression is reduced on normal vessels but still detectable in arteriovenous malformations of patients with hereditary haemorrhagic telangiectasia type I. Am J Pathol 2000, 156:911-923.
98. Kwei S., Stavrakis G., Takahas M., et al. Early adaptive responses of the vascular wall during venous arterialization in mice. Am J Pathol 2004, 164:81-89.
99. Begbie M.E., Wallace G.M.F., Shovlin C.L. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century. Postgrad Med J 2003, 79:18-24.
100. Cottin V., Plauchu H., Bayle J.-Y., Barthelet M., Revel D., Cordier J.F. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med 2004, 169:994-1000.
101. Olivieri C., Lanzarini L., Pagella F., Semino L., Corno S., Valacca C., et al. Echocardiographic screening discloses increased values of pulmonary artery systolic pressure in 9 of 68 unselected patients affected with hereditary hemorrhagic telangiectasia. Genet Med 2006, 8:183-190.
102. Girerd B., Montani D., Coulet F., et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 2010, 181:851-861.
103. Plauchu H., de Chadarévian J.-P., Bideau A., Robert J.-M. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989, 32:291-297.
104. Letteboer T., Mager H., Snijder R., et al. Genotype-phenotype relationship for localization and age distribution of telangiectases in hereditary hemorrhagic telangiectasia. Am J Med Genet A 2008, 146A:2733-2739.
105. th edition) 2010, 1261-1273. Elsevier-Saunders, Pennsylvania. R.J. Mason, C. Broaddus, T. Martin, M.D.. King, D.M.D. Schraufnagel, J.F. Murray, J.A. Nadel (Eds.).
106. Livneh A., Langevitz P., Morag B., Catania A., Pras M. Functionally reversible hepatic arteriovenous fistulas during pregnancy in patients with hereditary hemorrhagic telangiectasia. South Med J 1988, 81:1047-1049.
107. Gammon R.B., Miska A.K., Keller F.S. Osler-Weber-Rendu disease and pulmonary arteriovenous fistulas. Deterioration and embolotherapy during pregnancy. Chest 1990, 98:1522-1524.
108. Swinburne A.J., Fedulla A.J., Gangemi R., Mijangos J.A. Hereditary telangiectasia and multiple pulmonary arteriovenous fistulas. Clinical deterioration during pregnancy. Chest 1986, 89:459-460.
109. Shovlin C.L., Winstock A.R., Peters A.M., Jackson J.E., Hughes J.M.B. Medical complications of pregnancy in hereditary haemorrhagic telangiectasia. Quart J Med 1995, 88:879-887.
110. Kjeldsen A., Kjeldsen J. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2000, 95:415-418.
111. Pasculli G., Resta F., Guastamacchia E., Di Gennaro L., Suppressa P., Sabbà C. Health-related quality of life in a rare disease: hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease. Qual Life Res 2004, 13:1715-1723.
112. Lennox P., Hitchings A., Lund V., Howard D. The SF-36 health status questionnaire in assessing patients with epistaxis secondary to hereditary hemorrhagic telangiectasia. Am J Rhinol 2005, 19:71-74.
113. Aassar O.S., Friedman C.M., White R.I. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 1991, 101:977-980.
114. Lund V., Howard D. A treatment algorithm for the management of epistaxis in hereditary haemorrhagic telangiectasia. Am J Rhinol 1999, 13:319-322.
115. Sabba C., Pasculli G., Suppressa P., et al. Life expectancy in patients with hereditary haemorrhagic telangiectasia. QJM 2006, 99:327-334.
116. Morgan T., McDonald J., Anderson C., et al. Intracranial haemorrhgae in infants and children with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome). Pediatrics 2002, 109.
117. de Gussem E.M., Edwards C.P., Westermann C.J.J., Faughnan M.E., Mager J.J. Life expectancy of parents with hereditary hemorrhagic telangiectasia. Hematol Meet Rep 2009, 3(4):11-12.
118. Goodwin J., Nisenbaum R., Edwards C., Faughnan M.E. Survival in hereditary hemorrhagic telangiectasia. Hematol Meet Rep 2009, 3(4):12.
119. Snyder L.H., Doan C.A. Clinical and experimental studies in human inheritance-is the homozygous form of multiple telangiectasia lethal?. J Lab Clin Med 1944, 29:1211-1216.
120. Karabegovic A., Shinawi M., Cymerman U., Letarte M. No live individual homozygous for a novel endoglin mutation was found in a consanguineous Arab family with hereditary haemorrhagic telangiectasia. J Med Genet 2004, 41(11):e119.
121. El-Harith el H.A., Kuhnau W., Schmidtke J., et al. Hereditary hemorrhagic telangiectasia is caused by the Q490X mutation of the ACVRL1 gene in a large Arab family: support of homozygous lethality. Eur J Med Genet 2006, 49:323-330.
122. Wooderchak W., Gedge F., McDonald M., et al. Hereditary hemorrhagic telangiectasia: two distinct ENG deletions in one family. Clin Genet 2010, [Electronic publication ahead of print]. doi:10.1111/j.1399-0004.2010.01418.x.
123. Shovlin C.L., Scott J. Inherited diseases of the vasculature. Ann Rev Physiol 1996, 58:483-507.
124. Shovlin C.L. Molecular studies on adenosine deaminase deficiency and hereditary haemorrhagic telangiectasia. Clin Sci 1998, 94:207-218.
125. Shovlin C, Haslett C, Lamb J. The molecular and cellular basis of disease. In: Haslett C, Chilvers E, Hunter J, Boon N, eds. Davidson's Principles and Practice of Medicine 18th Edn. Edinburgh: Churchill Livingstone; 1999:1-56, and 1128-1131.
126. Letteboer T., Harradine K., Quigley D., et al. Genetic modification of the hereditary haemorrhagic telangiectasia phenotype. Hematol Meet Rep 2007, 1:26-27.
127. Gallione C., Aylsworth A., Beis J., et al. Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome. Am J Med Genet A 2010, 152A:333-339.
128. Cole S.G., Begbie M.E., Wallace G.M.F., Shovlin C.L. A new locus for hereditary haemorrhagic telangiactasia (HHT3) maps to chromosome 5. J Med Genet 2005, 42:577-582.
129. Govani F, Shovlin C. SNP mapping of the hereditary haemorrhagic telangiectasia (HHT)3 locus on chromosome 5 excludes Sprouty 4, VE-cadherin 2 and other interval genes. Journal of Angiogenesis Research 2010;2:15. http://doi:10.1186/2040-2384-2-15.
130. Bayrak-Toydemir P., McDonald J., Akarsu N., et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet 2006, 140:2155-2162.
131. Shoukier M., Teske U., Weise A., Engel W., Argyriou L. Characterization of five novel large deletions causing hereditary haemorrhagic telangiectasia. Clin Genet 2008, 73:320-330.
132. Shovlin C., Oh S.P. Hereditary haemorrhagic telangiectasia. Molecular basis of lung disease. Insights from rare lung disorders. 1st ed. 2010, 167-188. Humana Press, ISBN-13: 978-1588299635. F.X. McCormack, R.J. Panos, B.C. Trapnell (Eds.).
133. Toporsian M., Jerkic M., Zhou Y., et al. Spontaneous adult-onset pulmonary arterial hypertension attributable to increased endothelial oxidative stress in a murine model of hereditary hemorrhagic telangiectasia. Arterioscler Thromb Vasc Biol 2010, 30:509-517.
134. Harrison R.E., Flanagan J.A., Sankelo M., et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003, 40:865-871.
135. Abdalla S.A., Gallione C.J., Barst R.J., et al. Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia. Eur Respir J 2004, 23:373-377.
136. Massagué J., Gomis R. The logic of TGFbeta signaling. FEBS Lett 2006, 580:2811-2820.
137. Groppe J., Hinck C., Samavarchi-Tehrani P., et al. Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol Cell 2008, 29:157-168.
138. ten Dijke P., Arthur H. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007, 8:857-869.
139. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
140. Guo X., Wang X-F. Signaling cross-talk between TGF-β/BMP and other pathways. Cell Res 2009, 19:71-88.
141. Upton P., Davies R., Trembath R., Morrell N. BMP and activin type-II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J Biol Chem 2009, 284:15794-15804.
142. Pardali E., Goumans M.J., Ten Dijke P. Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol 2010, [Jul 23, Electronic publication ahead of print]. doi:10.1016/j.tcb.2010.06.006.
143. Abdalla S., Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006, 43:97-110.
144. Barbara N.P., Wrana J.L., Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1997, 274(2):584-594.
145. Lopez-Novoa J.M., Bernabeu C. The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol 2010, [Jul 23, Electronic publication ahead of print]. doi:10.1152/ajpheart.01251.2009.
146. Blanco F.J., Santibanez J.F., Guerrro-Esteo M., Langa C., Vary C.P., Bernabeu C. Interactions and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 2005, 204:574-584.
147. Goumans M.J., Valdimarsdottir G., Itoh S., Rosendahl A., Sideras P., ten Dijke P. Balancing the activation state of the endotheliumvia two distinct TGF-beta type I receptors. EMBO J 2002, 21:1743-1753.
148. Lebrin F., Goumans M.J., Jonker L., et al. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 2004, 23:4018-4028.
149. Pece-Barbara N., Vera S., Kathirkamathamby K., et al. Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta1 with higher affinity receptors and an activated Alk1 pathway. J Biol Chem 2005, 280:27800-27808.
150. David L., Mallet C., Mazerbourg S., Feige J.J., Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 2007, 109:1953-1961.
151. Scharpfenecker M., van Dinther M., Liu Z., et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 2007, 120:964-972.
152. Park S.O., Lee Y.J., Seki T., et al. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 2008, 111:633-642.
153. Bourdeau A., Dumont D.J., Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 1999, 104:1343-1351.
154. Satomi J., Mount R.J., Toporsian M., et al. Cerebral vascular abnormalities in a murine model of hereditary hemorrhagic telangiectasia. Stroke 2003, 34:783-789.
155. Srinivasan S., Hanes M.A., Dickens T., et al. A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet 2003, 12:473-482.
156. Knudson A.G. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985, 45:1437-1443.
157. Matsubara S., Bourdeau A., ter Brugge K., Wallace C., Letarte M. Analysis of endoglin expression in normal brain tissue and in cerebral arteriovenous malformations. Stroke 2000, 31:2653-2660.
158. Arthur H.M., Ure J., Smith A.J.H., et al. Endoglin, an ancillary TGFbeta receptor, is required for extra-embryonic angiogenesis and plays a key role in heart development. Dev Biol 2000, 217:42-53.
159. Urness L., Sorensen L., Li D. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 2000, 26:328-331.
160. Oh S.P., Seki T., Goss K.A., et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 2000, 97:2626-2631.
161. Shovlin C.L. Supermodels and disease: insights from the HHT mice. J Clin Invest 1999, 104.
162. Carvalho R.L., Itoh F., Goumans M.J., et al. Compensatory signalling induced in the yolk sac vasculature by deletion of TGFbeta receptors in mice. J Cell Sci 2007, 120:4269-4277.
163. Sorensen L.K., Brooke B.S., Li D.Y., Urness L.D. Loss of distinct arterial and venous boundaries in mice lacking endoglin, a vascular-specific TGFbeta coreceptor. Dev Biol 2003, 261:235-250.
164. Mancini M., Terzic A., Conley B., Oxburgh L., Nicola T., Vary C. Endoglin plays distinct roles in vascular smooth muscle cell recruitment and regulation of arteriovenous identity during angiogenesis. Dev Dyn 2009, 238:2479-2493.
165. Gerhardt H., Golding M., Fruttiger M., et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003, 161:1163-1177.
166. Gaengel K., Genove G., Armulik A., Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 2009, 29:630-638.
167. Sato Y., Rifkin D.B. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta1-like molecule by plasmin during co-culture. J Cell Biol 1989, 109:309-315.
168. Carvalho R., Jonker L., Goumans M., et al. Defective paracrine signalling by TGFbeta in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia. Development 2004, 131:6237-6247.
169. Letarte M., McDonald M.L., Li C., et al. Reduced endothelial secretion and plasma levels of transforming growth factor-ß1 in patients with hereditary haemorrhagic telangiectasia type 1. Cardiovasc Res 2005, 68:155-164.
170. Mahmoud M., Borthwick G., Hislop A., Arthur H. Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH. Lab Invest 2009, 89:15-25.
171. Li C., Guo B., Ding S., et al. TNF alpha down-regulates CD105 expression in vascular endothelial cells: a comparative study with TGF beta 1. Anticancer Res 2003, 23:1189-1196.
172. Torsney E., Charlton R., Parums D., Collis M., Arthur H.M. Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res 2002, 51:464-470.
173. Toporsian M., Gros R., Kabir M., et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 2005, 96:684-692.
174. Maire R., Schnewlin G., Bollinger A. Videomikroskopische Untersuchungen von Telangiektasien bei Morbus Osler und Sclerodermie. Schweiz med Wschr 1986, 116:335-338.
175. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 2003, 58:470-484.
176. Greene M., Miles R. Burden of disease in the UK scoping study. NIHR 2008.
177. Riviere S., Pelenc D., Dupuis Girod S., et al. Hereditary haemorrhagic telangiectasia and venous thromboembolism. Hematology Meeting Rep 2009, 3(4):54-55.
178. Flieger D., Hainke S., Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006, 85:631-632.
179. Massoud O., Youssef W., Mullen K. Resolution of hereditary hemorrhagic telangiectasia and anemia with prolonged [alpha]-interferon therapy for chronic hepatitis C. J Clin Gastroenterol 2004, 38:377-379.
180. Wheatley-Price P., Shovlin C.L., Chao D. Interferon for metastatic renal cell cancer causing regression of hereditary haemorrhagic telangiectasia. J Clin Gastroenterol 2005, 39:344-345.
181. Sabbà C., Gallitelli M., Palasciano G. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. N Engl J Med 2001, 345:926.
182. Saba H.I., Morelli G.A., Logrono L.A. Treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. New Engl J Med 1994, 330:1789-1790.
183. Van Cutsem E., Rutgeerts P., Vantrappen G. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 1990, 335:953-955.
184. British National Formulary: Royal Pharmaceutical Society of Great Britain British Medical Association; 2010.
185. Loges S., Roncal C., Carmeliet P. Development of targeted angiogenic medicine. J Thromb Haemost 2009, 7:21-33.
186. Sadick H., Riedel F., Naim R., et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005, 90:818-828.
187. Sadick H., Naim R., Gossler U., Hormann K., Riedel F. Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density. Int J Mol Med 2005, 15:15-19.
188. Tseng J., Glisson B., Khuri F., et al. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer Res 2001, 92:2364-2373.
189. Figg W., Dahut W., Duray P., et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001, 7:1888-1893.
190. Kurstin R. Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease. Oncology (Willeston Park) 2002, 16:21-24.
191. Pérez-Encinas M., Rabuñal Martínez M., Bello López J. Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia?. Haematologica 2002, 87:ELT34.
192. Therapontos C., Erskine L., Gardner E., Figg W., Vargesson N. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci 2009, 106:8573-8578.
193. Vargesson N. Thalidomide-induced limb defects: resolving a 50-year-old puzzle. Bioessays 2009, 31:1327-1336.
194. Akhurst R.J. Taking thalidomide out of rehab. Nat Med 2010, 16:370-372.
195. Porteous M.E.M., Burn J., Proctor S.J. Hereditary haemorrhagic telangiectasia: a clinical analysis. J Med Genet 1992, 29:527-530.
196. Shovlin C.L., Hughes J.M.B., Tuddenham E.G.D., et al. A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3. Nat Genet 1994, 6:205-209.
197. Letteboer T.G., Zewald R.A., Kamping E.J., et al. Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients. Hum Genet 2005, 116:8-16.
198. Prigoda NL, Savas S, Abdalla SA, et al. Hereditary haemorrhagic telangiectasia: mutation detection, test sensitivity and novel mutations. J Med Genet. 2006;43:722-8.
199. Bayrak-Toydemir P., McDonald J., Mao R., et al. Likelihood ratios to assess genetic evidence for clinical significance of uncertain variants: hereditary hemorrhagic telangiectasia as a model. Exp Mol Pathol 2008, 85:45-49.
200. McDonald J., Gedge F., Burdette A., et al. Multiple sequence variants in hereditary hemorrhagic telangiectasia cases: illustration of complexity in molecular diagnostic interpretation. J Mol Diagn 2009, 11:569-575.
201. Ng P.C., Hennikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003, 31:3812-3814.
202. SIFT. http://blocks.fhcrc.org/sift/SIFT.html.
203. Polyphen. http://genetics.bwh.harvard.edu/pph/.
204. Hewes R.C., Auster M., White R.I. Cerebral embolism-first manifestation of pulmonary arteriovenous malformation in patients with hereditary hemorrhagic telangiectasia. Cardiovasc Interv Radiol 1985, 8:151-155.
205. Haitjema T., Westermann C.J.J., Overtoom T.T.C., et al. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)-new insights in pathogenesis, complications, and treatment. Arch Intern Med 1996, 156:714-719.
206. Felix S., Jeannin S., Goizet C., et al. Stroke following pulmonary arteriovenous fistula embolization in a patient with HHT. Neurology 2008, 71:2012-2014.
207. Westermann C.J., Mager J.J., Mauser H.W., Overtoom T.T. Stroke following pulmonary arteriovenous fistula embolization in a patient with HHT. Neurology 2008, 73:1427-1427.
208. Lasjaunias P., Mahadevan J., Krings T., Ozanne A., Alvarez H. Cerebro medullary arteriovenous locations in children and adults with HHT. Haematol Meet Rep 2007, 1:43.
209. Buis D.R., Vandertop W.P. Gamma knife surgery and arteriovenous malformations. J Neurosurg Pediatr 2008, 2:229.
210. Klimo P., Rao G., Brockmeyer D. Pediatric arteriovenous malformations: a 15-year experience with an emphasis on residual and recurrent lesions. Childs Nerv Syst 2007, 23:31-37.
211. da Costa L., Thines L., Dehdashti A.R., et al. Management and clinical outcome of posterior fossa arteriovenous malformations: report on a single-centre 15-year experience. J Neurol Neurosurg Psychiatry 2009, 80:376-379.
212. Fulbright R.K., Chaloupka J.C., Putman C.M., et al. MR of hereditary hemorrhagic telangiectasia: prevalence and spectrum of cerebrovascular malformations. Am J Neuroradiol 1998, 19:477-484.
213. Willemse R.B., Mager J.J., Westermann C.J.J., Overtoom T.T., Mauser H., Wolbers J.G. Bleeding risk of cerebrovascular malformations in hereditary haemorrhagic telangiectasia. J Neurosurg 2000, 92:779-784.
214. Easey A.J., Wallace G.M.F., Hughes J.M., Jackson J.E., Taylor W.J., Shovlin C.L. Should asymptomatic patients with hereditary haemorrhagic telangiectasia (HHT) be screened for cerebral vascular malformations? Data from 22,061years of HHT patient life. J Neurol Neurosurg Psych 2003, 74:743-748.
215. Curie A., Lesca G., Cottin V., Edery P., Bellon G., Faughnan M.E., et al. Long-term follow-up in 12 children with pulmonary arteriovenous malformations: confirmation of hereditary hemorrhagic telangiectasia in all cases. J Pediatr Surg 2007, 151:299-306.
216. Al-Saleh S., Mei-Zahav M., Faughnan M.E., MacLusky I.B., Carpenter S., Letarte M., et al. Screening for pulmonary and cerebral arteriovenous malformations in children with hereditary haemorrhagic telangiectasia. Eur Respir J 2009, 34:875-881.
217. White R.I. Controlling haemorrhage in HHT- search for the "magic bullet": reflections from the Yale HHT Centre. Hematology Meeting Rep 2009, 3(4):19-20.
218. Bown S.G., Swain C.P., Storey D.W., et al. Endoscopic laser treatment of vascular anomalies of the upper gastrointestinal tract. Gut 1985, 26:1338-1348.
219. Office of Dietary Supplements. 2010. http://odsodnihgov/factsheets/ironasp.
220. Vegetarian Society. Iron information sheet. http://www.vegsoc.org/info/iron.html.
221. Vase P., Lorentzen M. Histological findings following oestrogen treatment of hereditary haemorrhagic telangiectasia. A controlled double-blind investigation. J Laryngol Otol 1983, 97:427-429.
222. Kurstin R. Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease. Oncology (Williston Park) 2002, 16:21-24.
223. Zangari M., Fink L.M., Elice F., Zhan F., Adcock D.M., Tricot G.J. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009, 27:4865-4873.
224. Cohen M.H., Gootenberg J., Keegan P., Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007, 12:713-718.
225. Shovlin C.L., Govani F.S. Hereditary haemorrhagic telangiectasia and genetic thrombophilia. Eur J Hum Genet 2009, 18:405-406.
226. Intercollegiate Stroke Working Party National clinical guideline for stroke 2008, Royal College of Physicians.
227. Shovlin C. Ischaemic stroke and thrombolysis- time to consider the HHT question. BMJ 2009; http://www.bmj.com/cgi/eletters/339/nov11_1/b4584.
228. Chan P. Antibiotic prophylaxis for patients with hereditary hemorrhagic telangiectasia. J Am Acad Derm 1992, 26:282-283.
229. Pelage J.P., Blivet S., Blondel J.H., et al. Embolization of ruptured pulmonary arteriovenous malformations in HHT patients. Hematol Meet Rep 2009, 3(4):25-26.